ADD
Andrew D. Dickinson Portfolio
Invests via GILEAD SCIENCES Inc. | Managed by Andrew D. Dickinson
Invests via GILEAD SCIENCES Inc.
Managed by Andrew D. Dickinson
Automatically Tracked
Andrew D. Dickinson Profile
With a diverse background in financial services, Andrew D. Dickinson has established himself as a key figure in corporate finance and strategic development. He is known for his experience leading organizations through critical phases of growth and transformation. His tenure at various public companies has honed his skills in driving operational efficiency and market expansion initiatives, making him an influential player in the industry. Through thoughtful leadership and stakeholder engagement, he consistently leverages business acumen to foster innovation and profitability within complex organizational frameworks.
With a diverse background in financial services, Andrew D. Dickinson has established himself as a key figure in corporate finance and strategic development. He is known for his experience leading organizations through critical phases of growth and transformation. His tenure at various public companies has honed his skills in driving operational efficiency and market expansion initiatives, making him an influential player in the industry. Through thoughtful leadership and stakeholder engagement, he consistently leverages business acumen to foster innovation and profitability within complex organizational frameworks.
Investment Philosophy & Strategy
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
33.56%
Gain -1.68%
Monthly
1.35%
Yearly
17.53%
Drawdown
17.04%
$1.28B
Equity
Holdings
$1.28B
Investment
$1.05B
$512.12M
Profit -$33.98M
Realized
$285.19M
Unrealized
$226.93M
Dividends
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
-1.68%
Profit
-$33.98M
Win %
66%
This Week
Compared To Last Week
Gain
-7.29%
Profit
-$100.43M
Win %
66%
This Month
Compared to last month
Gain
-10.29%
Profit
-$146.54M
Win %
66%
This Year
Compared to last year
Gain
-28.42%
Profit
-$530.97M
Win %
70%
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 26 | Longs Won 8/26 30% | Profit Factor 13.94 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $63.74M |
| Average Win $68.96M | Best Trade (Jun 29) $256.26M | Sharpe Ratio -86.3 |
| Average Loss -$2.2M | Worst Trade (Dec 30) -$12.88M | Z-Score 1.15 (74.85%) |
| Commissions $0 | Avg. Trade Length 10m 2w 3d | Expectancy $19.7M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.02% | 0.21% | 1.35% | 6.75% | 28.01% |
| Consecutive Losing Trades | 581 | 523 | 465 | 407 | 349 | 291 | 232 | 174 | 116 | 58 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
 ASMB Assembly Biosciences Inc. | 4.98M | $106.6M | $99.84M | - | -$6.76M | -6.34% | -2.479% |
 GLPG Galapagos NV American Depositary Receipt | 16.71M | $461.73M | $461.73M | - | - | - | 0.0 |
 KYTX Kyverna Therapeutics, Inc. | 4.13M | $15.43M | $23.75M | - | $8.31M | 53.88% | -3.601% |
 RCUS Arcus Biosciences Inc. | 31.42M | $458.31M | $686.63M | - | $228.32M | 49.82% | -4.251% |
 XLO Xilio Therapeutics, Inc. | 650,389 | $8.73M | $5.79M | - | -$2.93M | -33.61% | -1.22% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Andrew D. Dickinson?
The largest contributions to the portfolio's profits come from the following stocks: Arcellx, Inc - $256.26M, Tango Therapeutics Inc - $25.78M, and Merus N.V - $23.58M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Cypherpunk Technologies Inc - $12.88M, Kalaris Therapeutics, Inc - $3.88M, Hookipa Pharma Inc - $1.42M, Allogene Therapeutics Inc - $1.16M, and ImageneBio, Inc - $653,394.37. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are Andrew D. Dickinson's monthly returns?
Andrew D. Dickinson's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Andrew D. Dickinson's strategy be considered aggressive or moderate?
Andrew D. Dickinson's strategy can be described as moderate. It balances growth potential with risk management, showing a willingness to accept some volatility while still maintaining a relatively structured and diversified approach.
Should beginners follow Andrew D. Dickinson's strategy?
Andrew D. Dickinson's strategy may be suitable for beginners, but with some caution. While the overall approach is not overly complex, it still involves a certain level of risk and variability. Beginners should be prepared for occasional fluctuations and ensure they understand the strategy before trying to follow it.
2026 © Marketlog. All Rights Reserved.
